PN 101 RS
Alternative Names: PN-101-RSLatest Information Update: 09 Sep 2025
At a glance
- Originator PAEAN Biotechnology
- Class Antihypertensives; Antiparkinsonians; Eye disorder therapies; Hepatoprotectants
- Mechanism of Action Mitochondria replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Eye disorders; Hearing loss; Parkinson's disease
- Discontinued Adult respiratory distress syndrome; Non-alcoholic steatohepatitis; Preeclampsia
Most Recent Events
- 09 Sep 2025 Discontinued - Preclinical for Adult respiratory distress syndrome in South Korea (Parenteral) (PAEAN Biotechnology pipeline; September 2025)
- 09 Sep 2025 Discontinued - Preclinical for Non-alcoholic steatohepatitis in South Korea (Parenteral) (PAEAN Biotechnology pipeline; September 2025)
- 09 Sep 2025 Discontinued - Preclinical for Preeclampsia in South Korea (Parenteral) (PAEAN Biotechnology pipeline; September 2025)